Clear Product FocusThe company is singularly focused on a total artificial heart for severe heart failure, a durable strategic position. If clinical and regulatory milestones succeed, the device targets a persistent, high-need patient population with long product lifetimes and recurring service opportunities, supporting multi-year commercial potential and strategic partnerships.

Low Financial LeverageModest debt levels provide structural financial flexibility during the lengthy medtech development cycle. Low leverage reduces near-term default risk and leaves capacity to fund clinical programs via equity, partnerships, or targeted debt, which is important for a pre-revenue device developer that will need capital before commercial cash flows appear.

Established R&D And Regulatory PathwayActive R&D and explicit regulatory preparation signal the company is progressing toward commercialization, a durable value driver in medtech. Successful navigation of approvals would create high barriers to entry and a long product lifecycle, supporting sustainable revenue and follow-on consumables or service revenues.

Bears Say

Persistent Cash BurnThe company has recurring negative operating and free cash flow, indicating it cannot self-fund development. Over a multi-month horizon this necessitates external financing, increasing dilution risk, potentially delaying trials or commercialization if capital markets tighten, and placing pressure on strategic execution.

Pre-revenue OperationsLack of meaningful product revenue means there's no demonstrated market uptake or validated unit economics. This structural gap increases execution risk over the next several months as commercialization depends on successful clinical outcomes, regulatory approvals, and subsequent scaling of manufacturing and distribution.

Eroding Equity BaseDeclining shareholders' equity over multiple years reflects cumulative losses and likely prior funding dilution. Continued erosion constrains financial flexibility, raises the likelihood of further equity raises on unfavorable terms, and can impair the company’s ability to negotiate partnerships or raise capital without significant dilution.

7820 FAQ

What was Scandinavian Real Heart AB’s price range in the past 12 months?

Scandinavian Real Heart AB lowest stock price was €1.03 and its highest was €3.03 in the past 12 months.

What is Scandinavian Real Heart AB’s market cap?

Scandinavian Real Heart AB’s market cap is €13.10M.

When is Scandinavian Real Heart AB’s upcoming earnings report date?

Scandinavian Real Heart AB’s upcoming earnings report date is May 14, 2026 which is in 79 days.

How were Scandinavian Real Heart AB’s earnings last quarter?

Currently, no data Available

Is Scandinavian Real Heart AB overvalued?

According to Wall Street analysts Scandinavian Real Heart AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Scandinavian Real Heart AB pay dividends?

Scandinavian Real Heart AB does not currently pay dividends.

What is Scandinavian Real Heart AB’s EPS estimate?

Scandinavian Real Heart AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Scandinavian Real Heart AB have?

Scandinavian Real Heart AB has 9,997,408 shares outstanding.

What happened to Scandinavian Real Heart AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Scandinavian Real Heart AB?

Currently, no hedge funds are holding shares in DE:7820

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Scandinavian Real Heart AB

Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. It engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, PulsePump, and Sternal Prosthesis products. The company was incorporated in 2007 and is based in Västerås, Sweden.